Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

Introduction: This study evaluated the cost-effectiveness of abemaciclib plus fulvestrant (ABE + FUL) vs. palbociclib plus fulvestrant (PAL + FUL), ribociclib plus fulvestrant (RIB + FUL) and fulvestrant monotherapy (FUL) as second-line treatment for hormone receptor-positive and human epidermal gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yingcheng, Rui, Mingjun, Guan, Xin, Cao, Yingdan, Chen, Pingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206485/
https://www.ncbi.nlm.nih.gov/pubmed/34150798
http://dx.doi.org/10.3389/fmed.2021.658747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206485/
https://www.ncbi.nlm.nih.gov/pubmed/34150798
http://dx.doi.org/10.3389/fmed.2021.658747

Ejemplares similares